STAGE III RENAL CELL CANCER AJCC V8
Clinical trials for STAGE III RENAL CELL CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III RENAL CELL CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III RENAL CELL CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for rare kidney cancer
Disease control OngoingThis study tests whether combining two drugs—axitinib (which blocks cancer cell growth) and nivolumab (which helps the immune system fight cancer)—works better than nivolumab alone for a rare kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial includes a…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
New drug combo shows promise in shrinking advanced kidney tumors before surgery
Disease control OngoingThis study tests whether giving two drugs—lenvatinib and pembrolizumab—before surgery can shrink tumors in people with locally advanced kidney cancer that hasn't spread to other organs. About 18 participants will receive the combination for 12 weeks before their operation. The go…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
Could a superfruit boost immunotherapy for kidney cancer?
Disease control OngoingThis early-stage trial tests whether adding camu camu, a prebiotic fruit, to standard immunotherapy (nivolumab and ipilimumab) is safe and effective for people with advanced kidney cancer. About 31 participants will receive the combination to see if it improves gut bacteria linke…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New drug targets Hard-to-Treat cancers with rare gene flaw
Disease control OngoingThis study tests a drug called adavosertib in adults with advanced solid tumors that have a missing or broken SETD2 gene. The drug works by blocking enzymes that cancer cells need to grow. Researchers want to see if it can shrink tumors or keep them stable for at least 6 months.
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC
-
New combo therapy shows promise for tough kidney cancer
Disease control OngoingThis study tests whether adding the targeted therapy cabozantinib to standard immunotherapy (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer. About 1,175 adults with kidney cancer that has spread will receive either the usual treatment or the usual …
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:05 UTC
-
New hope for kidney cancer: which drug combo works best after immunotherapy fails?
Disease control OngoingThis study tests two treatment options for people with advanced kidney cancer that has spread and continued to grow after immunotherapy. One group gets a combination of two drugs (lenvatinib and everolimus), while the other gets a single drug (cabozantinib). The goal is to see wh…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 09, 2026 12:09 UTC
-
New drug cocktail shows promise for Hard-to-Treat urinary cancers
Disease control OngoingThis early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 08, 2026 13:04 UTC
-
Could a Pre-Surgery drug shrink kidney tumors?
Disease control OngoingThis phase 2 study tested the drug cabozantinib in 22 people with advanced kidney cancer that had not spread. The drug was given before surgery to see if it could shrink tumors. The goal was to make surgery easier and improve long-term outcomes.
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 05, 2026 12:09 UTC